Detalhe da pesquisa
1.
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
N Engl J Med
; 379(11): 1017-1027, 2018 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30207920
2.
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet
; 387(10023): 1075-1084, 2016 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827074
3.
Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
Eur Neurol
; 63(5): 311-7, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20453514
4.
Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
Eur Neurol
; 63(2): 101-6, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20090344
5.
Headache in multiple sclerosis.
Curr Pain Headache Rep
; 14(4): 316-20, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20514531
6.
Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study.
Eur Neurol
; 61(1): 27-32, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-18948697
7.
Fatigue is not associated with impaired function of regulatory T cells in untreated patients with multiple sclerosis.
Eur Neurol
; 62(6): 321-6, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19752558
8.
Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients.
Eur Neurol
; 59(3-4): 136-42, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18057900
9.
Habituation of the auditory startle response in cervical dystonia and Parkinson's disease.
Eur Neurol
; 59(3-4): 172-8, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18230875
10.
Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.
Mult Scler J Exp Transl Clin
; 4(2): 2055217318778610, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29854416
11.
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.
Ann Clin Transl Neurol
; 5(3): 346-356, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29560379
12.
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
J Neurol
; 254(1): 67-77, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17273808
13.
A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.
Mult Scler J Exp Transl Clin
; 3(3): 2055217317730096, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28989795
14.
CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis.
J Neuroimmunol
; 180(1-2): 178-84, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17011048
15.
Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.
Eur Neurol
; 65(4): 231-2, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21454981
16.
Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de-escalation and escalation.
Eur J Neurol
; 17(11): e105, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20722710
17.
Natalizumab and beyond.
Eur Neurol
; 64(4): 236-40, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20820105
18.
Longitudinal changes in self-reported walking ability in multiple sclerosis.
PLoS One
; 10(5): e0125002, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25932911
19.
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
JAMA Neurol
; 72(1): 31-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25419615
20.
Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson's disease.
J Neurol
; 249(7): 824-8, 2002 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12140664